DE60036199T2 - Proteaseresistente flint-analoge - Google Patents

Proteaseresistente flint-analoge Download PDF

Info

Publication number
DE60036199T2
DE60036199T2 DE60036199T DE60036199T DE60036199T2 DE 60036199 T2 DE60036199 T2 DE 60036199T2 DE 60036199 T DE60036199 T DE 60036199T DE 60036199 T DE60036199 T DE 60036199T DE 60036199 T2 DE60036199 T2 DE 60036199T2
Authority
DE
Germany
Prior art keywords
flint
seq
analog
analogs
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60036199T
Other languages
German (de)
English (en)
Other versions
DE60036199D1 (de
Inventor
Radmila Indianapolis MICANOVIC
Radhakrishnan Carmel RATHNACHALAM
Derrick Ryan Fishers WITCHER
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Application granted granted Critical
Publication of DE60036199D1 publication Critical patent/DE60036199D1/de
Publication of DE60036199T2 publication Critical patent/DE60036199T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Surgery (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
DE60036199T 1999-03-30 2000-03-20 Proteaseresistente flint-analoge Expired - Lifetime DE60036199T2 (de)

Applications Claiming Priority (15)

Application Number Priority Date Filing Date Title
US12683999P 1999-03-30 1999-03-30
US126839P 1999-03-30
US14007399P 1999-06-21 1999-06-21
US140073P 1999-06-21
US14707199P 1999-08-04 1999-08-04
US147071P 1999-08-04
US16052499P 1999-10-20 1999-10-20
US160524P 1999-10-20
US16066999P 1999-10-21 1999-10-21
US160669P 1999-10-21
US17274499P 1999-12-20 1999-12-20
US172744P 1999-12-20
US17818400P 2000-01-26 2000-01-26
US178184P 2000-01-26
PCT/US2000/006418 WO2000058466A2 (en) 1999-03-30 2000-03-20 Protease resistant flint analogs

Publications (2)

Publication Number Publication Date
DE60036199D1 DE60036199D1 (de) 2007-10-11
DE60036199T2 true DE60036199T2 (de) 2008-05-21

Family

ID=27568834

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60036199T Expired - Lifetime DE60036199T2 (de) 1999-03-30 2000-03-20 Proteaseresistente flint-analoge

Country Status (8)

Country Link
EP (1) EP1165781B1 (cg-RX-API-DMAC7.html)
JP (1) JP4590504B2 (cg-RX-API-DMAC7.html)
AT (1) ATE371737T1 (cg-RX-API-DMAC7.html)
AU (1) AU3739500A (cg-RX-API-DMAC7.html)
CA (1) CA2368767C (cg-RX-API-DMAC7.html)
DE (1) DE60036199T2 (cg-RX-API-DMAC7.html)
ES (1) ES2291197T3 (cg-RX-API-DMAC7.html)
WO (1) WO2000058466A2 (cg-RX-API-DMAC7.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69837996T2 (de) 1997-01-14 2008-02-28 Human Genome Sciences, Inc. Tumornekrosefaktor-rezeptoren 6 alpha& 6 beta
US7285267B2 (en) 1997-01-14 2007-10-23 Human Genome Sciences, Inc. Tumor necrosis factor receptors 6α & 6β
WO1999014330A1 (en) 1997-09-18 1999-03-25 Genentech, Inc. DcR3 POLYPEPTIDE, A TNFR HOMOLOG
CA2368760A1 (en) * 1999-03-30 2000-10-05 Eli Lilly And Company Flint polypeptide analogs
AU1189101A (en) * 1999-10-20 2001-04-30 Eli Lilly And Company Therapeutic applications of flint polypeptides
WO2002060947A2 (en) * 2001-02-01 2002-08-08 Eli Lilly And Company Glycoforms a fas ligand inhibitory protein analog
JP2005506282A (ja) * 2001-02-01 2005-03-03 イーライ・リリー・アンド・カンパニー Flintグリコフォーム
EP1447093A1 (en) 2003-02-14 2004-08-18 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Inhibition of the CD95 ligand/receptor system for the treatment of neurological disorders and injuries
CA3112788A1 (en) 2018-09-05 2020-03-12 Arizona Board Of Regents On Behalf Of Arizona State University Oncolytic virus platform to treat hematological cancer

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69837996T2 (de) * 1997-01-14 2008-02-28 Human Genome Sciences, Inc. Tumornekrosefaktor-rezeptoren 6 alpha& 6 beta
WO1999014330A1 (en) * 1997-09-18 1999-03-25 Genentech, Inc. DcR3 POLYPEPTIDE, A TNFR HOMOLOG
HUP0102067A2 (hu) * 1998-03-30 2001-10-28 Eli Lilly And Co. A TNF receptorcsaládba tartozó érett FLINT (mFLINT) polipeptid vagy más néven az OPG3 terápiás alkalmazásai

Also Published As

Publication number Publication date
AU3739500A (en) 2000-10-16
CA2368767A1 (en) 2000-10-05
CA2368767C (en) 2008-12-30
JP4590504B2 (ja) 2010-12-01
ES2291197T3 (es) 2008-03-01
ATE371737T1 (de) 2007-09-15
EP1165781A2 (en) 2002-01-02
EP1165781B1 (en) 2007-08-29
WO2000058466A3 (en) 2001-01-11
WO2000058466A2 (en) 2000-10-05
DE60036199D1 (de) 2007-10-11
JP2002539829A (ja) 2002-11-26

Similar Documents

Publication Publication Date Title
JP5887441B2 (ja) Rage融合タンパク質
DE69716905T2 (de) Analoge des glucagon ähnlichen peptides -2
DE69434053T2 (de) Verkürzter keratinocytenwachstumsfaktor(kgf)mit erhöhter biologischer aktivität
DE60219611T2 (de) Modifizierte annexin-proteine und verhinderung und behandlung von thrombose
DE60121808T2 (de) Verwendung eines polypeptids, welches die extrazelluläre domäne von il-20ra und il-20rb enthält, zur behandlung von entzündungen
DE69017753T3 (de) Tumor-Nekrosefaktor-Bindungsprotein II, seine Reinigung und spezifische Antikörper
JP4219404B2 (ja) 新規なアグーティ関連遺伝子
DE69132814T2 (de) Neues insulinähnliches wachstumsfaktor bindendes protein igfbp-5
EP1727833A1 (de) Rekombinante polypeptide der mitglieder der tnf ligandenfamilie und deren verwendung
JP2018535964A (ja) 線維芽細胞増殖因子(fgf)1アナログによるステロイド誘導性高血糖の処置
DE60221510T2 (de) Das nk1 fragment des hepatocytwachstumfaktors/dispersionsfaktors (hgf/sf), varianten davon und deren verwendung
KR20000016159A (ko) 락토페린 변이체와 이의용도
RU2426745C2 (ru) Рекомбинантный химерный белок фактора ингибирования нейтрофилов и гиругена и содержащая его фармацевтическая композиция
KR20070008510A (ko) 케모킨 변이체의 치료적 용도
DE60313168T2 (de) Antagonisten für cxcr3-bindende cxc-chemokine
DE69132813T2 (de) Genetisches igfbp-5 rodierendes material
DE69131979T2 (de) Genetisches igfbp-4 rodierendes material
JP4590504B2 (ja) プロテアーゼ耐性flint類似体
DE69935296T2 (de) IP3 bindendes Polypeptid mit hoher Affinität
DE69233155T2 (de) Insulinartigen wachstumsfaktor bindendes protein
DE69831084T2 (de) Beta-defensine
JP2002539828A (ja) Flintポリペプチドアナログ
JP2009513689A (ja) 神経学的疾患の治療、及び/又は予防のためのsdf−1の使用
CN112616315A (zh) C末端的cdnf和manf片段、包含它们的药物组合物及其用途
DE69018357T2 (de) Mutein von HST-1 und seine Herstellung.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8328 Change in the person/name/address of the agent

Representative=s name: KROHER, STROBEL RECHTS- UND PATENTANWAELTE, 80336

8328 Change in the person/name/address of the agent

Representative=s name: DR. SCHOEN & PARTNER, 80336 MUENCHEN